Hanmi Pharma of South Korea announced its fourth major out-licensing this year, a $960 million deal with Janssen for a diabetes-obesity drug; Denmark’s LEO Pharma paid $727 million for global rights to Astellas’ dermatology assets; Medtronic and Sequoia Capital partnered on a $60 million investment fund to support China device startups; BioDuro, a China-US CRO, merged its US operations with Formex, a CMO located in San Diego; WuXi PharmaTech and Eli Lilly will collaborate to develop a Lilly cardiovascular drug in China; ASLAN Pharma of Singapore and Hyundai Pharm will jointly develop an ASLAN molecule for cancer in South Korea; China will once again allow IPOs after a four-month suspension to prop up stock prices; Cellular Biomedicine opened a GMP manufacturing facility in the PKUCare Industrial Park of Beijing; and Hutchison MediPharma started a US Phase I clinical trial of sulfatinib in patients with solid tumors.
Help employers find you! Check out all the jobs and post your resume.
